Correction to: Blood Cancer Journal https://doi.org/10.1038/s41408-025-01212-0, published online 7 February 2025
In Figure 1, the trial periods and notable time points for the trials shown, have been amended to indicate the start dates and dates of data availability. The FDA and EMA withdrawal dates were also amended to indicate the dates of withdrawal rather than the dates of decision not to renew the accelerated/conditional approval. Additionally, for the DREAMM-8 trial, the BPd regimen was erroneously shown as BVd. This has been corrected and dosing of belantamab mafodotin has been updated. In Table 1 the DREAMM-3 primary analysis was clarified and some reference numbering was updated throughout the publication.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mukhopadhyay, P., Abdullah, H.A., Opalinska, J.B. et al. Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. Blood Cancer J. 15, 44 (2025). https://doi.org/10.1038/s41408-025-01243-7
Published:
DOI: https://doi.org/10.1038/s41408-025-01243-7
